IGHE (Ligelizumab Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is designed as a research-grade biosimilar to Ligelizumab, targeting immunoglobulin E (IGHE), the heavy chain constant region of IgE antibodies. IgE plays a central role in type I hypersensitivity reactions and allergic responses by binding to high-affinity receptors (FcεRI) on mast cells and basophils, triggering degranulation and release of inflammatory mediators. Elevated IgE levels are associated with allergic diseases including asthma, chronic spontaneous urticaria, atopic dermatitis, and allergic rhinitis, making it a critical therapeutic target for managing IgE-mediated pathologies.

Ligelizumab is a high-affinity humanized anti-IgE monoclonal antibody. It binds to the Cε3 domain of IgE (significantly greater potency than omalizumab), which prevents IgE interaction with its receptors, inhibiting the activation of effector cells such as mast cells and basophils, thereby blocking the cascade of allergic reactions. This biosimilar antibody serves as a valuable research tool for investigating IgE-mediated immune mechanisms, studying allergic disease pathways, evaluating anti-IgE therapeutic strategies, and exploring the role of IgE in various inflammatory conditions. It enables researchers to examine IgE biology and develop novel approaches for treating allergic disorders.